2018
Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study
Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM. Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 527-533. PMID: 30179984, PMCID: PMC6203599, DOI: 10.1097/qai.0000000000001846.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHerpes zoster ratesHerpes zosterAging Cohort StudyUninfected adultsUninfected veteransVaccine receiptZoster vaccineCohort studyHIV serostatusStudy periodCART-treated individualsCombination antiretroviral therapyHIV-1 RNAHigh rateLow CD4Vaccine guidelinesZoster vaccinationAntiretroviral therapyVaccine ratesStudy endPharmacy dataEffective vaccinePLWHZoster
2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survivalComparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines
2016
Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality
Salinas JL, Rentsch C, Marconi VC, Tate J, Budoff M, Butt AA, Freiberg MS, Gibert CL, Goetz MB, Leaf D, Rodriguez-Barradas MC, Justice AC, Rimland D. Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. Clinical Infectious Diseases 2016, 63: 1423-1430. PMID: 27539575, PMCID: PMC5106607, DOI: 10.1093/cid/ciw564.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIncident acute myocardial infarctionVeterans Aging Cohort StudyCombination antiretroviral therapyCardiovascular risk factorsHIV-1 RNAVACS IndexHazard ratioMyocardial infarctionRisk factorsMultivariable proportional hazards modelsVACS Index scoreLast clinic visitAging Cohort StudyHuman immunodeficiency virusProportional hazards modelCART initiationAntiretroviral therapyCause mortalityCD4 countClinic visitsCohort studyOrgan injuryPrimary outcomeImmunodeficiency virusCause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factorsMortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2015
Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators
King JT, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC. Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators. JAMA Surgery 2015, 150: 343-351. PMID: 25714794, PMCID: PMC5015449, DOI: 10.1001/jamasurg.2014.2257.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionAntiretroviral therapyPostoperative mortalityHIV infectionHIV-1 RNAIncidence rate ratiosUninfected patientsVirus infectionCell countUninfected comparatorsSurgical outcomesSurgical proceduresCD4 cell count strataCharlson Comorbidity Index scoreCommon inpatient surgical proceduresHIV-1 RNA levelsThirty-day postoperative mortalityUndetectable HIV-1 RNAVeterans Health Administration healthcare systemElectronic medical record dataCombination antiretroviral therapyComorbidity Index scoreCoronary artery bypass
2014
Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy
Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, . Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PLOS ONE 2014, 9: e95061. PMID: 24728071, PMCID: PMC3984283, DOI: 10.1371/journal.pone.0095061.Peer-Reviewed Original ResearchConceptsSerious non-AIDS eventsNon-AIDS eventsComposite outcomeAntiretroviral therapyCardiovascular diseaseSuppressive combination antiretroviral therapyEnd-stage renal diseaseEndpoint review committeeFive-year KaplanNon-AIDS cancerCombination antiretroviral therapyHIV RNA levelsSerious adverse eventsSuppressive antiretroviral therapyCause of morbidityLarge international trialCause of deathStudies of interventionsPre-specified criteriaCause mortalityAdverse eventsAIDS eventsEffect of ageMeier estimatesBaseline factorsThe VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study
Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW, Justice AC, . The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. PLOS ONE 2014, 9: e92606. PMID: 24667813, PMCID: PMC3965438, DOI: 10.1371/journal.pone.0092606.Peer-Reviewed Original ResearchConceptsVACS IndexCombination antiretroviral therapyNet reclassification improvementHIV biomarkersCause mortalityC-statisticTreatment interventionsMulti-drug resistant HIVHarrel's c-statisticsRespective hazard ratiosKaplan-Meier estimatesProportional hazards modelImproved scoresAntiretroviral studiesAntiretroviral therapyHazard ratioResistant HIVReclassification improvementRestricted IndexTreatment responseStudy interventionRisk scoreHazards modelVAC indexMortalityLong-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, EuroCoord F, Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla P, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher H, De Wit S, Burkholder G, Teira R, Justice A, Sterling T, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle S, Sterne J, Boulle A, Brodt H, Casabona J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Mocroft A, Obel N, Kitahata M, Lampe F, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Ingle S, May M, Sterne J, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause M, Ghosn J, Leport C, Reiss P, Wit F, Prins M, Bucher H, Sabin C, Gibb D, Fätkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Hamouda O, Gussenheimer-Bartmeyer B, Noguera-Julian A, Antinori A, Monforte A, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miró J, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Judd A, Conejo P, Haerry D, Weller I, Casabona J, Costagliola D, d'Arminio-Monforte A, Battegay M, de Wit S, Del Amo J, Grarup J, Chêne G, Colin C, Schwimmer C, Termote M, Kjaer J, Campbell M, Raben D, Battegay M, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, Monforte A, del Amo J, Dorrucci M, Egger M, Engsig F, Furrer H, Judd A, Kirk O, Lambotte O, Lewden C, Lodi S, Lodwick R, Matheron S, Meyer L, Miro J, Mocroft A, Monge S, Nakagawa F, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, Touloumi G, Wittkop L. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases 2014, 58: 1312-1321. PMID: 24457342, PMCID: PMC6276895, DOI: 10.1093/cid/ciu038.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyIncomplete CD4 recoveryCD4 countLong-term mortalityHIV-positive individualsViral suppressionRisk factorsCD4 recoveryInitiation of cARTLow initial CD4 countsCD4 cell recoveryLow CD4 countSustained viral suppressionInitial CD4 countHuman immunodeficiency virusCause of deathDifferent patient groupsCART initiationAntiretroviral therapyHIV cohortCox regressionImmunodeficiency virusPatient groupEligible individualsSubsequent mortality
2013
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, Research and Design of IeDEA F. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLOS ONE 2013, 8: e81355. PMID: 24367482, PMCID: PMC3867319, DOI: 10.1371/journal.pone.0081355.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive adultsMortality rateLife expectancyNorth American AIDS Cohort CollaborationHIV transmission risk groupTransmission risk groupsCombination antiretroviral therapyInjection drug useHIV-positive individualsCrude mortality rateComparable life expectancyBaseline CD4Cohort CollaborationART initiationCD4 countAge-specific mortality ratesRisk groupsPositive adultsGeneral populationDrug useAge 20Cells/AdultsAdditional yearAntiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failureThe Next Therapeutic Challenge in HIV: Polypharmacy
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs & Aging 2013, 30: 613-628. PMID: 23740523, PMCID: PMC3715685, DOI: 10.1007/s40266-013-0093-9.BooksConceptsAntiretroviral therapyHIV infectionSerious adverse drug eventsChronic antiretroviral therapyHarms of polypharmacyLifelong antiretroviral therapyRisk of polypharmacyCombination antiretroviral therapyNumber of medicationsAdverse drug eventsOrgan system injuryDecades of lifePhysiologic frailtyHIV patientsMore medicationsComorbid diseasesGeriatric syndromesImmune dysfunctionMedication adherenceMost HIVTherapeutic challengeChronic inflammationSystem injuryDrug eventsPolypharmacyMedical ICU Admission Diagnoses and Outcomes in Human Immunodeficiency Virus–Infected and Virus–Uninfected Veterans in the Combination Antiretroviral Era*
Akgün KM, Tate JP, Pisani M, Fried T, Butt AA, Gibert CL, Huang L, Rodriguez-Barradas MC, Rimland D, Justice AC, Crothers K. Medical ICU Admission Diagnoses and Outcomes in Human Immunodeficiency Virus–Infected and Virus–Uninfected Veterans in the Combination Antiretroviral Era*. Critical Care Medicine 2013, 41: 1458-1467. PMID: 23507717, PMCID: PMC4283206, DOI: 10.1097/ccm.0b013e31827caa46.Peer-Reviewed Original ResearchConceptsMedical ICU admissionVeterans Aging Cohort Study (VACS) IndexICU admissionAntiretroviral therapyRespiratory diagnosesMechanical ventilationVeterans Aging Cohort Study Index scoresUndetectable HIV-1 RNALogistic regressionStudy indicesVeterans Affairs Medical CenterCombination antiretroviral eraCritical care requirementsICU admission diagnosisMedical ICU careCombination antiretroviral therapyInfection/sepsisHIV-1 RNAHuman immunodeficiency virusMultivariable logistic regressionRoutine clinical biomarkersHigh mortality rateRevenue center codesAdmission diagnosisICU mortalityCohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug use
2012
Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States
Ohl ME, Perencevich E, McInnes DK, Kim N, Rimland D, Akgun K, Fiellin DA, Skanderson M, Wang K, Justice A. Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States. AIDS And Behavior 2012, 17: 174-180. PMID: 23080359, DOI: 10.1007/s10461-012-0325-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsConfidence IntervalsFemaleFollow-Up StudiesHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedOdds RatioResidence CharacteristicsRetrospective StudiesRural PopulationSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransConceptsRural-dwelling personsAntiretroviral therapyAntiretroviral adherenceUrban veteransRural-Urban Commuting Area codesVeterans Affairs Healthcare SystemCombination antiretroviral therapyHepatitis C infectionMultivariable logistic regressionSubstance use disordersC infectionHIV infectionRemote residentsHigh adherenceWhite raceVA healthcareUse disordersMedian proportionLogistic regressionAdherenceHealthcare systemRemote settingsTherapyInfectionFace barriersHIV infection, aging, and immune function
Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function. Current Opinion In Oncology 2012, 24: 506-516. PMID: 22759737, PMCID: PMC3695478, DOI: 10.1097/cco.0b013e328355e131.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV infectionCancer riskCancer preventionMore effective antiretroviral therapySustained antiretroviral therapyCombination antiretroviral therapyEffective antiretroviral therapyCancer risk factorsComplex chronic diseaseImmune system effectsSpecific cancer typesSystemic inflammationImmune dysfunctionChronic inflammationViral causeSmoking effectsLung cancerIndependent associationRisk factorsChronic diseasesHigh prevalenceCancer spectrumLiver cancerElevated riskDisparities in Rates of Spine Surgery for Degenerative Spine Disease Between HIV-Infected and Uninfected Veterans
King JT, Gordon AJ, Perkal MF, Crystal S, Rosenthal RA, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC. Disparities in Rates of Spine Surgery for Degenerative Spine Disease Between HIV-Infected and Uninfected Veterans. Spine 2012, 37: 612-622. PMID: 21697770, PMCID: PMC4507821, DOI: 10.1097/brs.0b013e318228f32d.Peer-Reviewed Original ResearchConceptsDegenerative spine diseaseVeterans Health AdministrationSpine diseaseSpine surgeryHealth AdministrationUninfected patientsCommon surgical sitesNinth Revision procedureSpine surgery ratesSurgical referral patternsCombination antiretroviral therapyHIV infection statusViral load levelsRisk-benefit ratioMultivariate Poisson regressionImpact of HIVComparator patientsUninfected veteransAntiretroviral therapyHIV infectionPrimary outcomeSpinal decompressionReferral patternsSurgery ratesDiagnosis codes
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosisCritical Illness in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy
Akgün KM, Huang L, Morris A, Justice AC, Pisani M, Crothers K. Critical Illness in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy. Annals Of The American Thoracic Society 2011, 8: 301-307. PMID: 21653532, PMCID: PMC3132789, DOI: 10.1513/pats.201009-060wr.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyAntiretroviral therapyICU admissionCritical illnessAdministration of ARTImpact of ARTProportion of deathsHIV eraOpportunistic infectionsHIVAIDS epidemicMore recent studiesIllnessPatientsAdmissionTherapyRecent studiesICUEtiologyInfectionMortalityIncidenceDiseaseAdministration